152,400 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Acquired by Swiss National Bank

Swiss National Bank acquired a new position in shares of Wave Life Sciences Ltd. (NASDAQ:WVEFree Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 152,400 shares of the company’s stock, valued at approximately $770,000. Swiss National Bank owned approximately 0.15% of Wave Life Sciences as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Laurion Capital Management LP raised its stake in shares of Wave Life Sciences by 5.1% during the 3rd quarter. Laurion Capital Management LP now owns 871,500 shares of the company’s stock worth $5,011,000 after acquiring an additional 42,662 shares in the last quarter. Newtyn Management LLC raised its stake in shares of Wave Life Sciences by 2.0% during the 3rd quarter. Newtyn Management LLC now owns 510,000 shares of the company’s stock worth $2,932,000 after acquiring an additional 10,000 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Wave Life Sciences by 4.3% during the 3rd quarter. Wellington Management Group LLP now owns 264,885 shares of the company’s stock worth $1,523,000 after acquiring an additional 10,830 shares in the last quarter. a16z Perennial Management L.P. bought a new position in shares of Wave Life Sciences during the 4th quarter worth approximately $392,000. Finally, Strs Ohio purchased a new stake in Wave Life Sciences during the 4th quarter worth approximately $382,000. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Price Performance

WVE stock opened at $6.18 on Friday. The firm’s fifty day simple moving average is $5.75 and its 200-day simple moving average is $5.26. The company has a market capitalization of $756.80 million, a P/E ratio of -11.88 and a beta of -0.99. Wave Life Sciences Ltd. has a 12 month low of $3.45 and a 12 month high of $7.67.

Wave Life Sciences (NASDAQ:WVEGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The company had revenue of $12.54 million for the quarter, compared to analysts’ expectations of $25.67 million. During the same period in the prior year, the company posted ($0.27) EPS. As a group, sell-side analysts forecast that Wave Life Sciences Ltd. will post -0.85 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on WVE shares. HC Wainwright boosted their target price on shares of Wave Life Sciences from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, March 7th. Wells Fargo & Company started coverage on shares of Wave Life Sciences in a research report on Wednesday, May 15th. They set an “overweight” rating and a $11.00 target price on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $5.00 target price on shares of Wave Life Sciences in a research report on Thursday, March 7th. Truist Financial reissued a “buy” rating and set a $17.00 target price on shares of Wave Life Sciences in a research report on Monday, April 1st. Finally, StockNews.com downgraded shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Wave Life Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $11.17.

Read Our Latest Analysis on WVE

Insider Activity at Wave Life Sciences

In related news, CFO Kyle Moran sold 15,630 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $6.17, for a total value of $96,437.10. Following the completion of the transaction, the chief financial officer now directly owns 33,921 shares in the company, valued at approximately $209,292.57. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 31.10% of the company’s stock.

Wave Life Sciences Company Profile

(Free Report)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

Further Reading

Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd. (NASDAQ:WVEFree Report).

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.